Cargando…
Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652497/ http://dx.doi.org/10.1186/2051-1426-3-S2-P435 |
| _version_ | 1782401766824869888 |
|---|---|
| author | Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Mougdil, Tarsem Feng, Zipei Dubay, Christopher Fisher, Brenda Koguchi, Yoshinobu Aung, Sandra Mederos, Eileen Bifulco, Carlo McNamara, Michael Bahjat, Keith S Redmond, William Ochoa, Augusto C Hu, Hong Ming Fox, Bernard Urba, Walter Hilton, Traci |
| author_facet | Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Mougdil, Tarsem Feng, Zipei Dubay, Christopher Fisher, Brenda Koguchi, Yoshinobu Aung, Sandra Mederos, Eileen Bifulco, Carlo McNamara, Michael Bahjat, Keith S Redmond, William Ochoa, Augusto C Hu, Hong Ming Fox, Bernard Urba, Walter Hilton, Traci |
| author_sort | Sanborn, Rachel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4652497 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46524972015-11-25 Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Mougdil, Tarsem Feng, Zipei Dubay, Christopher Fisher, Brenda Koguchi, Yoshinobu Aung, Sandra Mederos, Eileen Bifulco, Carlo McNamara, Michael Bahjat, Keith S Redmond, William Ochoa, Augusto C Hu, Hong Ming Fox, Bernard Urba, Walter Hilton, Traci J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4652497/ http://dx.doi.org/10.1186/2051-1426-3-S2-P435 Text en Copyright © 2015 Sanborn et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Mougdil, Tarsem Feng, Zipei Dubay, Christopher Fisher, Brenda Koguchi, Yoshinobu Aung, Sandra Mederos, Eileen Bifulco, Carlo McNamara, Michael Bahjat, Keith S Redmond, William Ochoa, Augusto C Hu, Hong Ming Fox, Bernard Urba, Walter Hilton, Traci Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title_full | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title_fullStr | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title_full_unstemmed | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title_short | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC |
| title_sort | preliminary analysis of immune responses in patients enrolled in a phase ii trial of cyclophosphamide with allogenic dribble vaccine alone (dpv-001) or with gm-csf or imiquimod for adjuvant treatment of stage iiia or iiib nsclc |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652497/ http://dx.doi.org/10.1186/2051-1426-3-S2-P435 |
| work_keys_str_mv | AT sanbornrachel preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT boulmaybrian preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT lirui preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT spielerbradley preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT happelkyle preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT paustianchristopher preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT mougdiltarsem preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT fengzipei preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT dubaychristopher preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT fisherbrenda preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT koguchiyoshinobu preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT aungsandra preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT mederoseileen preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT bifulcocarlo preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT mcnamaramichael preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT bahjatkeiths preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT redmondwilliam preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT ochoaaugustoc preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT huhongming preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT foxbernard preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT urbawalter preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT hiltontraci preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc |